Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATTERHORN-CN: perioperative durvalumab plus FLOT in resectable gastric or gastroesophageal junction cancer
CTR20263306Phase 3Active
- Sponsor
- MedImmune
- Start
- Sep 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by MedImmune. Started Sep 2026; status: active.
02
Drugs
durvalumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20263306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263306.